Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FERRIC-CABG Trial: Iron Isomaltoside for Perioperative Myocardial Injury in CABG ± Valve Surgery
2019-002661-35Phase 4Unknown
- Sponsor
- King's College London
- Start
- Nov 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronary arteriosclerosis, Cardiac valve disease (VHD) and Myocardial injury comparing Iron isomaltoside with Placebo (2 arms). Primary endpoint: Troponin T 72-hour area under the curve. Status: unknown.
02
Drugs
ferric derisomaltose
03
Conditions
coronary arteriosclerosisCardiac valve disease (VHD)Myocardial injury
Beyond the preview
Go deeper on 2019-002661-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002661-35.